Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eyegate Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01505088
First received: January 4, 2012
Last updated: March 28, 2013
Last verified: March 2013
  Purpose

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.


Condition Intervention Phase
Anterior Uveitis
Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution
Drug: Prednisolone Acetate (1%) Eyedrops
Drug: 100 mM sodium citrate buffer solution
Drug: Placebo Eyedrops
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Resource links provided by NLM:


Further study details as provided by Eyegate Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Proportion of patients with with ACC count of zero at Day 14 [ Time Frame: At Day 14 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Proportion of patients with ACC count of zero at Day 14


Secondary Outcome Measures:
  • Proportion of patients with ACC count of zero at Day 7 [ Time Frame: At Day 7 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Proportion of patients with ACC count of zero at Day 7

  • Proportion of patients with ACC count of zero at Day 28 [ Time Frame: At Day 28 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Proportion of patients with ACC count of zero at Day 28

  • Proportion of patients with ACC count of zero at Day 56 [ Time Frame: At Day 56 (plus or minus seven days) following the first study treatment ] [ Designated as safety issue: Yes ]
    The proportion of patients with ACC count of zero at Day 56

  • Mean change from baseline in ACC count and score at Day 7 [ Time Frame: At Day 7 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Mean change from baseline in ACC count and score at Day 7

  • Mean change from baseline in ACC count and score at Day 14 [ Time Frame: At Day 14 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Mean change from baseline in ACC count and score at Day 14

  • Mean change from baseline in ACC count and score at Day 28 [ Time Frame: At Day 28 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Mean change from baseline in ACC count and score at Day 28

  • Mean change from baseline in ACC count and score at Day 56 [ Time Frame: At Day 56 (plus or minus seven days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Mean change from baseline in ACC count and score at Day 56

  • Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 7 [ Time Frame: At Day 7 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 7

  • Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 14 [ Time Frame: At Day 14 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 14

  • Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 28 [ Time Frame: At Day 28 (plus or minus two days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 28

  • Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 56 [ Time Frame: At Day 56 (plus or minus seven days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Proportion of subjects with ACC count and score reduction from baseline of one or more units at Day 56

  • Time to anterior chamber cell count and score of zero [ Time Frame: Up to 56 days (plus or minus seven days) following the first study treatment ] [ Designated as safety issue: Yes ]
    Time to anterior chamber cell count and score of zero


Enrollment: 193
Study Start Date: December 2011
Study Completion Date: March 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Iontophoretic Dexamethasone Phosphate Ophthalmic Solution
Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution
Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
Drug: Placebo Eyedrops
Placebo Eyedrops
Other Name: Saline/ Benzalkonium Chloride (BAK) Ophthalmic Solution
Active Comparator: Prednisolone Acetate Ophthalmic Suspension (1%)
Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
Drug: Prednisolone Acetate (1%) Eyedrops
Prednisolone acetate (1%) eyedrops
Drug: 100 mM sodium citrate buffer solution
Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution

Detailed Description:

Anterior uveitis is a disorder of the eye associated with intraocular inflammation of the anterior portion of the uvea, particularly the iris and/or ciliary body. It is distinct from other iterations of uveitis such as posterior, diffuse and intermediate uveitis although it is the most common form of uveitis and accounts for approximately 75% of cases.

In a Phase 1/2 study (EGP-437-001), the delivery of EGP-437 (40 mg/mL dexamethasone phosphate solution) at four different iontophoresis dose levels was studied in 40 subjects with non-infectious anterior segment uveitis. The study demonstrated that a single EGP-437 treatment: lowered anterior chamber cell (ACC) scores in the majority of patients without requiring additional treatment; produced low short-term systemic exposure to dexamethasone and dexamethasone phosphate; and produced the most beneficial effects in the 1.6 and 4.8 mA-min dose groups; and caused mainly minor AEs and no non-ocular systemic corticosteroid mediated effects were observed.

The Phase 3 study is intended to confirm and extend the results from the Phase 2 study. The study is designed to assess the safety and efficacy Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA and accompanying placebo eyedrops in comparison to Ocular Iontophoresis with sodium citrate buffer solution 4.0 mA-min at 1.5 mA and accompanying prednisolone acetate (1%) eyedrops for the treatment of non-infectious anterior segment uveitis.

  Eligibility

Ages Eligible for Study:   12 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis defined as an anterior chamber cell count of ≥ 11 cells
  • Receive, understand, and sign a copy of the written informed consent form
  • Be able to return for all study visits and willing to comply with all study-related instructions

Exclusion Criteria:

  • Have uveitis of infectious etiology
  • Have active intermediate or posterior uveitis
  • Known positive HLA-B27 with a severe (4+) fibrinoid reaction
  • Have previous anterior segment uveitis episode in the study eye ≤ 4 weeks prior to baseline visit
  • Have used topical corticosteroid treatment in the study eye ≤ 48 hours prior to baseline visit
  • Have used oral corticosteroid within the past 14 days prior to baseline
  • Have received intravitreal or sub-Tenon corticosteroid treatment in the study eye within the past 6 months prior to baseline visit
  • Currently using prescribed nonsteroidal anti-inflammatory agents (i.e., use of over-the-counter dosages is allowable) or prescribed immunosuppressive agents, unless the dose has been stable for the last six weeks and no change in dosing is anticipated for the duration of the study
  • Have IOP ≥ 25 mmHg at baseline, a history of glaucoma, or require ocular anti-hypertensive medications in the study eye
  • Be known steroid intraocular pressure responders in either eye
  • Have open wounds/skin disease on the forehead area where the iontophoresis return electrode will be applied
  • Have severe lesions of the eyelids or the ocular surface impeding the application of the iontophoresis applicator
  • Have known allergy to dexamethasone or dexamethasone phosphate or any medication to be used in this study
  • Have history or diagnosis of ocular herpes, corneal lesion of suspected herpetic origin, or Behçet's disease
  • Have monocular or BCVA worse than 20/80 in the fellow eye
  • Have optic neuritis of any origin
  • Have clinically suspected or confirmed central nervous system or ocular lymphoma
  • Planning to undergo elective ocular surgery during the study
  • Have active hyphema, pars planitis, choroiditis, clinically significant macular edema, toxoplasmosis scar, or vitreous hemorrhage
  • Have severe/serious ocular pathology or medical condition which may preclude study completion
  • Have pacemaker and/or any other electrical sensitive support system
  • Be pregnant or lactating female, or female of childbearing age and using inadequate birth control method
  • Have participated in another investigational device or drug study within 30 days of baseline visit
  • Have significant Fuch's Corneal Dystrophy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01505088

  Show 39 Study Locations
Sponsors and Collaborators
Eyegate Pharmaceuticals, Inc.
Investigators
Principal Investigator: John D. Sheppard, M.D. Virginia Eye Consultants
  More Information

No publications provided

Responsible Party: Eyegate Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01505088     History of Changes
Other Study ID Numbers: EGP-437-004
Study First Received: January 4, 2012
Last Updated: March 28, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Eyegate Pharmaceuticals, Inc.:
Iontophoresis
Non-Infectious Anterior Segment Uveitis
Ophthalmology

Additional relevant MeSH terms:
Uveitis
Chorioretinitis
Uveitis, Anterior
Iridocyclitis
Uveal Diseases
Eye Diseases
Retinitis
Retinal Diseases
Choroiditis
Choroid Diseases
Uveitis, Posterior
Panuveitis
Iris Diseases
Pharmaceutical Solutions
Tetrahydrozoline
Dexamethasone acetate
Methylprednisolone acetate
Prednisolone acetate
Dexamethasone
Prednisolone
Methylprednisolone
Methylprednisolone Hemisuccinate
Dexamethasone 21-phosphate
Prednisolone hemisuccinate
Prednisolone phosphate
BB 1101
Citric Acid
Ophthalmic Solutions
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 22, 2014